

MAR 31 2003

TECH CENTER 1600/2900

#23/10
JRP
4/18/03



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: March 21, 2003

Signature:

(Harvey L. Cohen)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Cesaro et al

Application No.: 09/653,717

Group Art Unit: 1614

Filed: September 1, 2000

Examiner: R. Cook

For: USE OF NICOTINE OR DERIVATIVE
THEREOF FOR THE TREATMENT OF
NEUROLOGIC DISEASES, IN
PARTICULAR, PARKINSON DISEASE

X

Box RCE
Commissioner for Patents
Washington, DC 20231

AMENDMENT

Dear Sir:

In response to the official action mailed October 22, 2002, applicant submits the following amendments and remarks. Applicants' Request for Continued Examination is also enclosed.

IN THE CLAIMS

Insert new claims 45 and 46, as follows:

⁵⁶
45. (NEW) A method for improving the functionality of D1 and D2 dopaminergic receptors associated with neurodegenerative diseases, multi-systemic atrophy, or both, in a human mammal comprising administering over a long term period an effective dose of at least two drug components comprising as a first component nicotine or a nicotine derivative, and a second component comprising L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered in the absence of said first component and a dopaminergic agonist.

P'cont
⁵⁷₄₆. (NEW) A method for treating a neurodegenerative disease, a multi-systemic atrophy, or both, in a human mammal comprising administering over a long term period an effective dose of at least two drug components comprising as a first component, nicotine or a nicotine derivative, and a second component comprising L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered in the absence of said first component and a dopaminergic agonist.

**AMENDMENT TRANSMITTAL LETTER****Expedited Procedure**Application No.
09/653,717Filing Date
September 1, 2000Examiner
R. CookGroup Art Unit
1614


Applicant(s): Pierre Cesaro and Gabriel Villafane

Docket No.
EGYP 3.0-008Invention: USE OF NICOTINE OR DERIVATIVE THEREOF FOR THE TREATMENT OF
NEUROLOGIC DISEASES, INPARTICULAR, PARKINSON DISEASE**TO THE COMMISSIONER FOR PATENTS**

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	43	- 51 =	0	x	
Independent Claims	5	- 5 =	0	x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

☒ Large Entity☐ Small Entity☒ No additional fee is required for this amendment.☐ Please charge Deposit Account No. _____ in the amount of _____.
A duplicate copy of this sheet is enclosed.☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 12-1095
as described below. A duplicate copy of this sheet is enclosed.☒ Credit any overpayment.☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.
Harvey L. Cohen
Attorney Reg. No. 28,365Dated: March 21, 2003LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP
600 South Avenue, West
Westfield, New Jersey 07090
(908) 518-6425I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in
an envelope addressed to: **Box RCE**, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: March 21, 2003

Signature:  (Harvey L. Cohen)